UPDATED January 24, 2021 – Cardiovascular diseases are one of the major causes of fatality in the world. Over the years, the rate of deaths caused by cardiovascular diseases has decreased in some countries while dramatically increasing in others. The percentage of premature deaths from cardiovascular illness ranges from a low of 3% in nations with a high GDP of up to 49% in low-GDP nations. More than 250 million individuals across the worlds lost their lives due to coronary heart disease and cardiovascular diseases in 2011. According to cardiac stem cell research, each year heart illness kills significantly more humans than cancer. In recent years, Cardiometabolic and cardiovascular dangers in women have been growing at a fast rate and have killed a higher percentage of women than breast cancer has.
Therapeutic cardiomyocyte regeneration using hematopoietic mesenchymal stem cells. Replace dead cardiomyocytes with functionally integrated cardiac and vascular endothelial cells (cardiogenesis.) Decrease inflammation and Angiogenesis to increase blood vessel growth for the heart.
Causes of Coronary Artery Disease
Coronary Heart Disease “CHD” is also known as coronary artery disease “CAD.” CAD or CHD are conditions in which the coronary arteries are weakened due to plaque buildup in our blood circulatory system. The arteries are primarily responsible for providing blood and oxygen to the heart. Stem Cell Therapy for Heart Disease can be a good choice for those seeking a safe, non-surgical alternative treatment for most cardiac diseases, including Chronic Ischemic Arteries and Coronary Heart Disease.
Acute Coronary Syndromes – Coronary Thrombosis
- Unstable acute angina (chest pain) symptom occurs when the heart doesn’t get enough oxygen or blood flow. Symptoms vary, but for most patients, the symptoms start occurring more frequently over time during periods of rest. Over time the angina pain starts to last longer and feels more severe. Traditional treatments such nitroglycerin may be used but if left untreated the issue to result in a heart attack.
- NSTEMI or Non-ST segment elevation myocardial infarction is a type of heart attack that may not register on an electrocardiogram (ECG). There are, however, markers in blood tests that can be used to screen for events or damage to the heart muscle. For most NSTEMI patients, the artery blockage may be temporary or partial.
- STEMI or ST-segment elevation myocardial infarction is the other type of heart attack caused by a blockage in the blood supply. STEMI events affect large areas of cardiac tissue and can be measured by an ECG test or blood panels screening for the specific enzymatic activity and chemical markers. These biochemical markers in blood tests are known as cardiac risk markers of inflammation. The tests were developed from the earliest diagnostic markers of troponins (troponin complex) & Creatine kinase-MB (CK-MB)
Signs of Atherosclerosis & Coronary Plaque
Symptoms for patients with ischemic heart disease vary for all patients, but new blood tests and genetic testing for hereditary heart disease can be used as an early warning sign of acute coronary syndrome.
Plaque is produced because of the cholesterol, calcium, fat, and other substances found in the blood. When the plaque starts to build up in your arteries, you get diagnosed with a disease called atherosclerosis. The building up of the plaque takes place over many years. As time passes by, the plaque narrows your coronary arteries and thus hardens. This is the cause of the limited oxygen-rich blood in the heart.
The plague-infested region can also rupture, or break open. This forms a blood clot on the surface of the plaque. When this worsens, and the blood clot becomes more prominent, this disturbs the blood flow in the coronary artery. Moreover, angina or a heart attack might happen if your heart does not receive a regular flow of blood and fresh oxygen. Angina is a severe discomfort in the chest. It might feel like there is a pressure or squeezing inside your chest. The pain also might happen inside your neck, shoulders, arms, back or, jaw. Angina discomfort might even really feel like indigestion.
A heart attack happens when the regular flow of blood rich in oxygen to the section of the heart is disrupted or blocked. If this flow is not remedied immediately, the particular part of the heart will not function. Without immediate treatment, a heart attack can occur, and this may lead to death. With time, CHD will make the heart weaker, and this could result in peripheral neuropathy, arrhythmia, muscular atrophy, and often heart failure.
Heart disease is a condition where the heart cannot pump sufficient blood required by the body. Arrhythmia has something to do with the abnormal rhythm and rate of the heartbeat.
Signs of Coronary Heart Disease
CAD, CHD, and IHD Cardiomyopathy can happen due to many reasons, including environmental conditions, lifestyle, and genes. Some common risk factors for heart disease include:
- Lung diseases, i.e., Pulmonary Fibrosis
- Kidney diseases PKD or Diabetic Nephropathy
- Viral Infections
- Ischemic Strokes
- Abuse of alcohol or drugs
- Connective tissue disorders, i.e., Lupus
- Reaction to medications
- Exposure to industrial chemicals or toxins such as lead
Is Coronary Artery Disease Hereditary?
It is estimated that over 40% of all CAD cases might have some hereditary influence and the most commonly diagnosed genetic heart diseases include:
- Genetic Arrhythmia
- Pulmonary arterial hypertension
- Connective tissue disorders
- Hypertrophic Cardiomyopathy
- Hemorrhagic telangiectasia
- Congenital heart disease
- Brugada Syndrome
- Catecholaminergic polymorphic ventricular tachycardia
- Short QT Syndrome
- Long QT Syndrome
Diagnosis of Heart Disease
The clinical diagnosis of heart disease requires diagnostic tests and physical exams. A cardiologist uses several tests to determine the severity including Echocardiogram, Electrocardiogram (ECG), angiograms, CT coronary angiogram, heart Stress tests (nuclear stress test), Cardiac catheterization, and blood tests. The regeneration center offers a comprehensive list of genetic panels to screen for mutations in genes that lead to hereditary heart diseases using the following panels:
TNNC1, TNNI3, JUP,DOLK,TAZ,CAV3, CRYAB, CSRP3, DES,VCL,RBM20, RYR2, SCN5A, SGCD,TCAP, TMEM43, LAMP2, LMNA, MYBPC3,PKP2, PLN, PRKAG2, RAF1,EYA4,ABCC9,DSC2, DSG2, DSP, EMD, MYH7, MYL2, MYL3, ACTC1, ACTN2,GAA, GLA, HCN4, AGL, BAG3,TNNT2, TPM1,FHL1, FKRP, FKTN, FLNC, TTN, TTR, SLC22A5, CACNA1C, ANKRD1, DMD, CTNNA3,LDB3 and PDLIM3.
DNA screening tests are recommended for family members of patients who had sudden cardiac death. Early intervention is often key in managing the disease, so if the direct relatives of the deceased think they might carry an inherited disorder/gene mutation, then screening would be advised. We do not offer gene therapies to treat heart disease, but there are several clinical trials underway to cure genetic heart diseases. To help reduce any risk of developing Coronary Artery Disease and ischemic heart diseases consider making dietary changes and getting regular exercise.
TREATMENT PRECAUTIONS & RISKSPlease note Cardiac stem cell transplants are not appropriate for all cardiovascular diseases. Heart Cell Therapy, cardiac tissue, and cell engineering are limited options for those with severe heart muscle damage. Patients with severe scarring, late stage, or those with travel restrictions will not qualify for the 14-21 day treatment time needed. Please contact us for more information
New Treatment Options for Heart Disease
There are several methods to treat coronary artery disease depending on the stage, severity, and underlying cause of the condition. The first line of defense for patients with heart disease requires immediate lifestyle changes, medications, surgical procedures, or cardiac stem cell therapy to manage the disease.
Some common medications and non-surgical treatments for CHD, CAD & IHD include:
- Antiplatelet medications (Clopidogrel)
- Cholesterol-lowering medications (statins)
- Calcium channel blockers
- Percutaneous Coronary Revascularization
- Heart Stem cell therapy
Patients who do not respond well to medications or have reached a severe stage of heart disease might require surgery to restore and improve blood flow. Common surgical procedures for heart disease include:
- Open-heart surgery
- Coronary bypass surgery
- CABG: coronary artery bypass graft
- A balloon to widen a coronary artery
- Coronary artery stent
Treat Heart Disease with Stem Cells
Stem cell therapy is a new alternative,non-surgical treatment option and can help reverse heart disease.  The impact of enhanced stem cell therapies are better understood now more than ever, and The Heart Regeneration Center offers a unique and effective cardiac regeneration protocol depending on patients needs. Cardiac cell transplants and targeted paracrine signaling help rebuild a patient’s heart tissue by utilizing clinical grade hematopoietic mesenchymal stem cells. For most elderly patients or those with severe physical limitations, a combination of allogeneic cell therapy will be required. This option is only available for patients whose own cells are not sufficient or impotent due to age or other diseases. The stem cells are immune-system compatible and expanded from cardiosphere-derived stem cells to help assist replenish/replace damaged heart cells and reverse coronary heart disease symptoms.  The enriched stem cells are then placed them back into the heart generally via a process known as homing using multiple stage delivery over two weeks.
1 Year After Stem Cell Treatment for CHD
The benefits of having regenerative therapy to treat Acute coronary syndrome include:
- Reduction in the infarct size / Reduction in heart muscle scar 
- Improved regulation of O2 (Oxygen) Intake and Use 
- Greater Reduction in Angina 
- Noticeable improvement in the patients overall well-being and condition in Life.
- Long-term benefits (≥12 months) with measurable improvement in well-being & physical endurance.
- Reduction in heart muscle scar size, infarct size with reduction of cardiogenic shock
- Improvement of Left ventricular ejection fraction resulting in no need of rehospitalization
Treat Cardiovascular Diseases with Cardiopoietic Cells
- Chronic Heart disease
- Coronary artery disease
- Congestive Heart failure
- Coronary thrombosis
- Coronary artery atherosclerosis
- Ischemic heart disease (IHD)
- MI – Heart Attack
Total Number of Stem Cell Infusions: 2-8 Infusion of Endogenous Mesenchymal Cardiomyocyte cells & Exosome growth Factors (per Treatment stage requirement) Multiple Stages may be required for severe conditions
Cardiac Rehabilitation Post Treatment: Cardiac Rehabilitation therapy in Bangkok is optional and can be provided for a minimum of 2 hours per day and five days per week. Medical visas and accommodations for the patient and family/friends at an extended stay service apartment or hotel can also be included upon request.
Total Time Required for Cardiac Treatment is: Estimated around two weeks in total (depending on the patients’ medical needs)
Guidelines for Heart Stem Cell Treatment
Our cardiac regeneration treatment protocol is a comprehensive combination treatment and needs to be performed in multiple stages. For most patients, this will require the ability to travel to Thailand for the 2-3 week adjuvant therapy. Due to the varying degrees/severity of the patient and other underlying medical factors, the medical team will need to evaluate all potential patients before a prognosis can be provided. Upon acceptance, a detailed treatment plan will be provided to the patient that will include the specifics of the recommended medical protocol, the total length of stay required, along with a fixed price for all related medical costs. To begin the qualification process for the Regeneration Center Heart Disease treatment, please prepare all recent medical records such as an Echocardiogram, EKG, Tilt Table Heart CT Scan or SPECT exam (Single-photon emission computed tomography) and contact us today.
Published Clinical Citations
 ^ Arom, Kitipan V, Permyos Ruengsakulrach, and Vibul Jotisakulratana. 2008. Intramyocardial angiogenic cell precursor injection for cardiomyopathy in Thailand. Asian cardiovascular & thoracic annals, no. 2. https://www.ncbi.nlm.nih.gov/pubmed/18381874
 ^ Hou, Jingying, Lingyun Wang, Jieyu Jiang, Changqing Zhou, Tianzhu Guo, Shaoxin Zheng, and Tong Wang. 2013. Cardiac stem cells and their roles in myocardial infarction. Stem cell reviews and reports, no. 3. doi:10.1007/s12015-012-9421-4. https://www.ncbi.nlm.nih.gov/pubmed/23238707
 ^ Martinez, Paula F, and Marina P Okoshi. 2018. Genetic Risk in Coronary Artery Disease. Arquivos brasileiros de cardiologia, no. 1 (July 0). doi:S0066-782X2018000700062. https://www.ncbi.nlm.nih.gov/pubmed/30110045
 ^ Nartprayut, Kuneerat, Yaowalak U-Pratya, Pakpoom Kheolamai, Sirikul Manochantr, Methichit Chayosumrit, Surapol Issaragrisil, and Aungkura Supokawej. 2013. Cardiomyocyte differentiation of perinatally‑derived mesenchymal stem cells. Molecular medicine reports, no. 5 (March 4). doi:10.3892/mmr.2013.1356. https://www.ncbi.nlm.nih.gov/pubmed/23467912.
 ^ Pratumvinit, Busadee, Kanit Reesukumal, Kajohnkiart Janebodin, Nicholas Ieronimakis, and Morayma Reyes. 2013. Isolation, characterization, and transplantation of cardiac endothelial cells. BioMed research international (October 27). doi:10.1155/2013/359412. https://www.ncbi.nlm.nih.gov/pubmed/24282814
 ^ Varga, E, C Nemes, R P Davis, O Ujhelly, N Klincumhom, Z Polgar, S Muenthaisong, M K Pirity, and A Dinnyes. 2014. Generation of transgene-free mouse induced pluripotent stem cells using an excisable lentiviral system. Experimental cell research, no. 2 (February 18). doi:10.1016/j.yexcr.2014.02.006. https://www.ncbi.nlm.nih.gov/pubmed/24560743
 ^ Windmolders, Severina, Astrid De Boeck, Remco Koninckx, Annick Daniëls, Olivier De Wever, Marc Bracke, Marc Hendrikx, Karen Hensen, and Jean-Luc Rummens. 2013. Mesenchymal stem cell secreted platelet derived growth factor exerts a pro-migratory effect on resident Cardiac Atrial appendage Stem Cells. Journal of molecular and cellular cardiology (December 8). doi:10.1016/j.yjmcc.2013.11.016. https://www.ncbi.nlm.nih.gov/pubmed/24326234